ES2175028T3 - Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva. - Google Patents

Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva.

Info

Publication number
ES2175028T3
ES2175028T3 ES96203571T ES96203571T ES2175028T3 ES 2175028 T3 ES2175028 T3 ES 2175028T3 ES 96203571 T ES96203571 T ES 96203571T ES 96203571 T ES96203571 T ES 96203571T ES 2175028 T3 ES2175028 T3 ES 2175028T3
Authority
ES
Spain
Prior art keywords
paclitaxel
beta
prodrugs
prodrug
profarmacos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96203571T
Other languages
English (en)
Inventor
Bont Hendricus Barthelomeas De
Hidde Jacob Haisma
Ruben Geradus George Leenders
Vos Dick De
Johan Wilhelm Scheeren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmachemie BV
Original Assignee
Pharmachemie BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmachemie BV filed Critical Pharmachemie BV
Application granted granted Critical
Publication of ES2175028T3 publication Critical patent/ES2175028T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C263/00—Preparation of derivatives of isocyanic acid
    • C07C263/12—Preparation of derivatives of isocyanic acid from or via nitrogen analogues of carboxylic acids, e.g. from hydroxamic acids, involving a Hofmann, Curtius or Lossen-type rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS PROFARMACOS DE PACLITAXEL SOLUBLES EN AGUA, EN DONDE PACLITAXEL ESTA, A TRAVES DE SU FUNCIONALIDAD 2''-HIDROXILO, CONECTADO A UN GRUPO SEPARADOR SEPARABLE, EL CUAL ESTA EN CAMBIO INCORPORADO A UN GRUPO DE AZUCAR PREFERIBLEMENTE ENZIMATICAMENTE SEPARABLE. DICHOS PROFARMACOS SON RELATIVAMENTE NO TOXICOS Y PUEDEN SER UTILIZADOS EN EL TRATAMIENTO DE CANCER. PUEDEN SER SELECTIVAMENTE ACTIVADOS EN EL EMPLAZAMIENTO DEL TUMOR MEDIANTE LA ACCION DE ENZIMAS ENDOGENAS O ENZIMAS DIRIGIDAS, O MEDIANTE UN PROCEDIMIENTO NO ENZIMATICO. LA ENZIMA ES PREFERIBLEMENTE {BE}-GLUCORONIDASA, {BE}-GLUCOSIDASA O {BE}-GALACTOSIDASA. LA INVENCION TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN PROFARMACO DE PACLITAXEL COMO SE DEFINIA AQUI, EL CUAL COMPRENDE DICHO PROFARMACO CON UN PORTADOR FARMACEUTICAMENTE ACEPTABLE PARA PROPORCIONAR UNA FORMULACION SOLIDA O LIQUIDA PARA ADMINISTRACION.
ES96203571T 1995-12-29 1996-12-17 Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva. Expired - Lifetime ES2175028T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95203671 1995-12-29

Publications (1)

Publication Number Publication Date
ES2175028T3 true ES2175028T3 (es) 2002-11-16

Family

ID=8221031

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96203571T Expired - Lifetime ES2175028T3 (es) 1995-12-29 1996-12-17 Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva.

Country Status (10)

Country Link
US (1) US5760072A (es)
EP (1) EP0781778B1 (es)
JP (1) JPH09202796A (es)
AT (1) ATE216394T1 (es)
CA (1) CA2192424C (es)
DE (1) DE69620727T2 (es)
DK (1) DK0781778T3 (es)
ES (1) ES2175028T3 (es)
PT (1) PT781778E (es)
SI (1) SI0781778T1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038727A1 (en) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Medicament composite
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
WO1999018113A1 (fr) * 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US6989452B2 (en) * 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
CN1649600A (zh) 2002-02-28 2005-08-03 A&D生物科学公司 氟西汀及类似物的糖醛酰胺、苷和原酸酯苷及其应用
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
CA2490626A1 (en) * 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. Prodrug, medicinal utilization thereof and process for producing the same
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
US20080312162A1 (en) * 2004-10-08 2008-12-18 The Ohio State University Methods and Compositions for Enzyme-Specific Activation of Carbohydrate-Conjugated Prodrugs
FR2947455B1 (fr) 2009-07-01 2014-01-03 Centre Nat Rech Scient La dermaseptine b2 comme inhibiteur de la croissance tumorale
CN110227164B (zh) 2018-03-06 2021-11-23 江苏吉贝尔药业股份有限公司 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
WO2022008527A1 (en) * 2020-07-06 2022-01-13 Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen Polymeric micelles comprising glucuronide-prodrugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol

Also Published As

Publication number Publication date
ATE216394T1 (de) 2002-05-15
PT781778E (pt) 2002-08-30
JPH09202796A (ja) 1997-08-05
SI0781778T1 (en) 2002-10-31
DK0781778T3 (da) 2002-06-17
CA2192424C (en) 2002-01-22
EP0781778B1 (en) 2002-04-17
CA2192424A1 (en) 1997-06-30
US5760072A (en) 1998-06-02
DE69620727T2 (de) 2002-08-22
DE69620727D1 (de) 2002-05-23
EP0781778A1 (en) 1997-07-02

Similar Documents

Publication Publication Date Title
ES2175028T3 (es) Profarmacos de paclitaxel, metodo de preparacion asi como su uso en quimioterapia selectiva.
CA2336815A1 (en) Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
PT1183050E (pt) Processo para a produção de uma preparação farmacêutica injectável
WO1998000172A3 (en) Compositions and methods for altering the biodistribution of biological agents
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ATE212236T1 (de) Durch lysosomale enzyme spaltbare antitumor- wirkstoff-konjugate
DK0814777T3 (da) Stabile lipidholdige lægemiddelleveringskomplekser og fremgangsmåder til deres fremstilling
IL133585A0 (en) Soluble prodrugs of paclitaxel
ES2169414T3 (es) Amino-azucar citotoxico y derivados de azucares relacionados de indolopirrolocarbazoles.
DE69533615D1 (de) Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie
WO2001089571A3 (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
WO2005025512A3 (en) Cobalamin conjugates for anti-tumor therapy
CA2356959A1 (en) Water-insoluble drug delivery system
Kato et al. Antitumor activity of 1-β-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative
AU2207197A (en) Targeted site specific drug delivery compositions and method of use
NO995481L (no) Glykokonjugater av 20 (S)-camptothecin
FUJII et al. UCE1022, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from Paecilomyces
TWI265027B (en) Topical application of muscarinic analgesic drugs such as neostigmine
WO2004058143A3 (en) High specificity anticancer pharmacological drug system, drug synthesis, and drug development process
JPS5515445A (en) Introduction of amino-protecting group by microorganism
DE69031932T2 (de) Arylsulfatase
EP1132383A4 (en) NEW AGAROFURAN DERIVATIVES, THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS MEDICINE
JP2000078956A (ja) 飲食物および薬品

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 781778

Country of ref document: ES